This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.
Healthy adults
Subjects with a body weight of 50 kg or more and a BMI within the range of 18.0 to 29.9 kg/m²
History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease
Presence of acute disease symptoms within 28 days prior to the first dosing
History of any disease that may affect drug absorption, distribution, metabolism, or excretion
Hypersensitivity or history of clinically significant hypersensitivity to atorvastatin, telmisartan, drugs containing ingredients of the same class, or other medications (e.g., aspirin, antibiotics, dihydropyridine derivatives)
Single group
Atorvastatin Calcium
DrugHUC2-744-A
Telmisartan
DrugHUC2-744-B
AUCτ
Area Under the Curve of telmisartan, atorvastatin
Cmax,ss
Maximum concentration at steady state of telmisartan, atorvastatin
Cmax,ss
Maximum concentration at steady state of 2-hydroxy atorvastatin
AUCτ
Area Under the Curve of 2-hydroxy atorvastatin
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
